Objectives This study analyzed the safety of coronavirus disease 2019 (COVID-19) bivalent and monovalent booster vaccines, including the frequency of adverse events (AEs) such as myocarditis and pericarditis, in adolescents aged 12 to 17 years in the Republic of Korea. We aimed to share the safety profile of the COVID-19 bivalent vaccine booster doses.
Methods We analyzed the frequencies of AEs reported to the COVID-19 vaccination management system (CVMS) or self-reported through the text message survey (TMS). Diagnostic eligibility and causality with vaccines were compared using odds ratios (ORs) by vaccine type, and incidence rates per 100,000 person-days were calculated for confirmed cases of myocarditis and pericarditis following monovalent and bivalent booster doses.
Results In the CVMS, the AE reporting rate (per 100,000 doses) was lower after the bivalent booster (66.5) than after the monovalent booster (264.6). Among the AEs reported for both monovalent and bivalent vaccines 98.3% were non-serious and 1.7% were serious. According to the TMS, both local and systemic AEs were reported less frequently after the bivalent vaccination than after the monovalent vaccination in adolescents aged 12 to 17 years (p<0.001). The incidence rates per 100,000 person-days for confirmed myocarditis/pericarditis following monovalent and bivalent booster doses were 0.03 and 0.05, respectively; this difference was not statistically significant (OR, 1.797; 95% confidence interval, 0.210–15.386).
Conclusion AEs in 12- to 17-year-olds following the bivalent booster were less frequent than those following the monovalent booster in the Republic of Korea, and no major safety issues were identified. However, the reporting rates for AEs were low.
Objectives Between July 2, 2021, and September 20, 2022, a Mycobacterium bovis outbreak occurred among exhibition animals at a zoo in the Republic of Korea. This study was conducted to assess the likelihood of M. bovis transmission to human contacts through a contact investigation and to implement preventive treatment for latent tuberculosis infection (LTBI). Methods: In this descriptive study, the Korea Disease Control and Prevention Agency conducted a contact investigation, which included interviews, interferon-gamma release assay (IGRA) tests, and chest X-rays. Contacts underwent IGRA testing on 2 occasions: initial testing of 29 contacts (15 in the first cluster of infection and 14 in the second cluster) and follow-up testing of the 15 contacts in the first cluster. Results: The study included 29 participants, 18 of whom were male (62.1%) and 11 female (37.9%). The mean participant age was 37.3 years (standard deviation, 9.6 years). In the initial IGRA tests, 6 of the 29 participants tested positive, indicating a prevalence of 20.7%. Following prolonged exposure, 1 additional positive case was detected in follow-up testing, raising the prevalence of LTBI to 24.1%. None of the contacts had active tuberculosis. Among the 7 individuals with positive results, 2 (28.6%) underwent treatment for LTBI. Conclusion: This study faced challenges in confirming the transmission of M. bovis infection from infected animals to humans in the Republic of Korea. Nevertheless, adopting a One Health approach necessitates the implementation of surveillance systems and infection control protocols, particularly for occupational groups at high risk of exposure.
Objectives This study aimed to disseminate information on coronavirus disease 2019 (COVID-19) vaccine safety among adolescents aged 12 to 17 years in the Republic of Korea. Methods: Two databases were used to assess COVID-19 vaccine safety in adolescents aged 12 to 17 years who completed the primary Pfizer-BioNTech vaccination series. Adverse events reported to the web-based COVID-19 vaccination management system (CVMS) and collected in the text message-based system were analyzed. Results: From March 5, 2021 to February 13, 2022, 12,216 adverse events among 12- to 17-yearolds were reported to the CVMS, of which 97.1% were non-serious adverse events and 2.9% were serious adverse events, including 85 suspected cases of anaphylaxis, 74 suspected cases of myocarditis and/or pericarditis, and 2 deaths. From December 13, 2021 to January 26, 2022, 10,389 adolescents responded to a text message survey, and local/systemic adverse events were more common after dose 2 than after dose 1. The most commonly reported events following either vaccine dose were pain at the injection site, headache, fatigue/tiredness, and myalgia. Conclusion: The overall results are consistent with previous findings; the great majority of adverse events were non-serious, and serious adverse events were rare among adolescents aged 12 to 17 years following Pfizer-BioNTech COVID-19 vaccination.
Citations
Citations to this article as recorded by
Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents Jue Seong Lee, HyoSug Choi, Seung Hwan Shin, Myung-Jae Hwang, Sara Na, Jong Hee Kim, Sangshin Park, Yoonsun Yoon, Hyun Mi Kang, Bin Ahn, Kyoungsan Seo, Young June Choe Vaccine.2024; 42(14): 3333. CrossRef
Myopericarditis following COVID-19 vaccination in children: a systematic review and meta-analysis Ashiley Annushri Thenpandiyan, Ryan Ruiyang Ling, Robert Grignani, Megan Ruien Ling, Arthena Anushka Thenpandiyan, Bee Choo Tai, Jyoti Somani, Kollengode Ramanathan, Swee Chye Quek Singapore Medical Journal.2024;[Epub] CrossRef
Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea Mijeong Ko, Seontae Kim, Seok-Kyoung Choi, Seung Hwan Shin, Yeon-Kyeng Lee, Yunhyung Kwon Osong Public Health and Research Perspectives.2024; 15(4): 364. CrossRef
Association of new onset seizure and COVID‐19 vaccines and long‐term follow‐up: A systematic review and meta‐analysis Ali Rafati, Melika Jameie, Mobina Amanollahi, Yeganeh Pasebani, Nastaran Salimi, Mohammad Hosein Feyz Kazemi, Mana Jameie, Mohammad Yazdan Pasebani, Delaram Sakhaei, Fateme Feizollahi, Churl‐Su Kwon Epilepsia.2024; 65(10): 3010. CrossRef
Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis Peng Gao, Liang-Yu Kang, Jue Liu, Min Liu World Journal of Pediatrics.2023; 19(11): 1041. CrossRef
Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12–17 years Bao-Qiang Guo, Hong-Bin Li, Li-Qiang Yang Vaccine.2023; 41(28): 4067. CrossRef
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea Yeon-Kyeng Lee, Yunhyung Kwon, Yesul Heo, Eun Kyoung Kim, Seung Yun Kim, Hoon Cho, Seontae Kim, Mijeong Ko, Dosang Lim, Soon-Young Seo, Enhi Cho Clinical and Experimental Pediatrics.2023; 66(10): 415. CrossRef
Risk of Coronavirus Disease 2019 Messenger RNA Vaccination-Associated Myocarditis and Pericarditis – A Systematic Review of Population-Based Data Yen-Ching Lin, Chia-Hsuin Chang, Wei-Ju Su, Chin-Hui Yang, Jann-Tay Wang Risk Management and Healthcare Policy.2023; Volume 16: 2085. CrossRef
Suspected Myocarditis after mRNA COVID-19 Vaccination among South Korean Adolescents Mi Jin Kim, Jin Hee Kim, Hyun Ok Jun, Kyung Min Kim, Min Sub Jeung, Jun Sung Park Journal of Pediatric Infectious Diseases.2023;[Epub] CrossRef
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward Eliel Nham, Joon Young Song, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim Journal of Korean Medical Science.2022;[Epub] CrossRef
Objectives This study aimed to present data on reported adverse events following coronavirus disease 2019 (COVID-19) vaccination in Republic of Korea from February 26 to October 31, 2021, and to determine whether any significant patterns emerged from an analysis of the characteristics of suspected adverse event cases for each type of vaccine.
Methods Adverse events following COVID-19 vaccination reported by medical doctors and forensic pathologists were analyzed. Cases of suspected anaphylaxis were classified using the Brighton Collaboration definition.
Results By October 31, 2021, a total of 353,535 (0.45%) adverse events were reported after 78,416,802 COVID-19 vaccine doses. Of the adverse events, 96.4% were non-serious and 3.6% were serious. The most frequently reported adverse events were headache, myalgia, and dizziness. Of the 835 reported deaths after COVID-19 vaccination, 2 vaccine-related deaths were confirmed. Suspected anaphylaxis was confirmed in 454 cases using the Brighton Collaboration definition.
Conclusion The commonly reported symptoms were similar to those described in clinical trials. Most reported adverse events were non-serious, and the reporting rate of adverse events following COVID-19 vaccination was higher in women than in men (581 vs. 315 per 100,000 vaccinations). Confirmed anaphylaxis was reported in 5.8 cases per 1,000,000 vaccinations.
Citations
Citations to this article as recorded by
Anaphylaxis post-COVID-19 vaccinations in Singapore Li Fung Peck, Wang Woon Poh, Adena Theen Lim, Sally Bee Leng Soh, Mun Yee Tham, Belinda Pei Qin Foo, Amelia Jing Jing Ng, Patricia Suet Ling Ng, Pei San Ang, Cheng Leng Chan, Dorothy Su Lin Toh, Edmund Jon Deoon Lee, Amelia Santosa, Bernard Yu-Hor Thong, Singapore Medical Journal.2024;[Epub] CrossRef
A Nationwide Survey of mRNA COVID-19 Vaccinee’s Experiences on Adverse Events and Its Associated Factors Dongwon Yoon, Ha-Lim Jeon, Yunha Noh, Young June Choe, Seung-Ah Choe, Jaehun Jung, Ju-Young Shin Journal of Korean Medical Science.2023;[Epub] CrossRef
Temporal association between the age-specific incidence of Guillain-Barré syndrome and SARS-CoV-2 vaccination in Republic of Korea: a nationwide time-series correlation study Hyunju Lee, Donghyok Kwon, Seoncheol Park, Seung Ri Park, Darda Chung, Jongmok Ha Osong Public Health and Research Perspectives.2023; 14(3): 224. CrossRef
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea Yeon-Kyeng Lee, Yunhyung Kwon, Yesul Heo, Eun Kyoung Kim, Seung Yun Kim, Hoon Cho, Seontae Kim, Mijeong Ko, Dosang Lim, Soon-Young Seo, Enhi Cho Clinical and Experimental Pediatrics.2023; 66(10): 415. CrossRef
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management Nicoletta Luxi, Alexia Giovanazzi, Alessandra Arcolaci, Patrizia Bonadonna, Maria Angiola Crivellaro, Paola Maria Cutroneo, Carmen Ferrajolo, Fabiana Furci, Lucia Guidolin, Ugo Moretti, Elisa Olivieri, Giuliana Petrelli, Giovanna Zanoni, Gianenrico Senna, BioDrugs.2022; 36(4): 443. CrossRef
Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea Seontae Kim, Insob Hwang, Mijeong Ko, Yunhyung Kwon, Yeon-Kyeng Lee Osong Public Health and Research Perspectives.2022; 13(3): 230. CrossRef
Incidence and Characteristics of Adverse Events after COVID-19 Vaccination in a Population-Based Programme Laura Bonzano, Olivera Djuric, Pamela Mancuso, Lidia Fares, Raffaele Brancaccio, Marta Ottone, Eufemia Bisaccia, Massimo Vicentini, Alessia Cocconcelli, Alfonso Motolese, Rostyslav Boyko, Paolo Giorgi Rossi, Alberico Motolese Vaccines.2022; 10(7): 1111. CrossRef
Global Predictors of COVID-19 Vaccine Hesitancy: A Systematic Review Carla Pires Vaccines.2022; 10(8): 1349. CrossRef
Anaphylaxis and Related Events Following COVID‐19 Vaccination: A Systematic Review Pradipta Paul, Emmad Janjua, Mai AlSubaie, Vinutha Ramadorai, Beshr Mushannen, Ahamed Lazim Vattoth, Wafa Khan, Khalifa Bshesh, Areej Nauman, Ibrahim Mohammed, Imane Bouhali, Mohammed Khalid, Dalia Zakaria The Journal of Clinical Pharmacology.2022; 62(11): 1335. CrossRef
Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years Seontae Kim, Yeseul Heo, Soon-Young Seo, Do Sang Lim, Enhi Cho, Yeon-Kyeng Lee Osong Public Health and Research Perspectives.2022; 13(5): 382. CrossRef
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward Eliel Nham, Joon Young Song, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim Journal of Korean Medical Science.2022;[Epub] CrossRef
Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea Yunhyung Kwon, Insob Hwang, Mijeong Ko, Hyungjun Kim, Seontae Kim, Soon-Young Seo, Enhi Cho, Yeon-Kyeng Lee Epidemiology and Health.2022; 45: e2023006. CrossRef
Objectives We investigated the impact of the coronavirus disease 2019 (COVID-19) pandemic on tuberculosis (TB) management in the Republic of Korea (ROK).
Methods This retrospective cross-sectional study used nationwide ROK TB notification data (98,346 cases) from 2017 to 2020. The median time from the onset of TB symptoms to treatment initiation and the compliance rates with the required timing for notification and individual case investigations were measured and compared across periods and regions affected by the COVID-19 epidemic.
Results TB diagnosis during the COVID-19 pandemic was delayed. The median time to TB treatment initiation (25 days) in 2020 increased by 3 days compared to that of the previous 3 years (22 days) (p<0.0001). In the outbreak in Seoul, Incheon, and Gyeonggi province during August, the time to TB diagnosis was 4 days longer than in the previous 3 years (p=0.0303). In the outbreak in Daegu and Gyeongbuk province from February to March 2020, the compliance rate with the required timing for individual case investigations was 2.2%p points lower than in other areas in 2020 (p=0.0148). For public health centers, the rate was 13%p lower than in other areas (80.3% vs. 93.3%, p=0.0003).
Conclusion TB diagnoses during the COVID-19 pandemic in the ROK were delayed nationwide, especially for patients notified by public-private mix TB control hospitals. TB individual case investigations were delayed in regional COVID-19 outbreak areas (Daegu and Gyeongbuk province), especially in public health centers. Developing strategies to address this issue will be helpful for sustainable TB management during future outbreaks.
Citations
Citations to this article as recorded by
A Review of the Impact of Patent Medicine Vendors in Driving Community Tuberculosis Case Finding in the COVID-19 Pandemic in Nigeria Arinze Emmanuel Ajogwu, Onwubiko Iheanyichukwu Samuel, Nnanyelugo Longinus Ochike, Uzoma Chidinma Ajegbo, Chinedu Paschal Maduka Matrix Science Medica.2024; 8(2): 33. CrossRef
Tuberculosis: Republic of Korea, 2021 Jinsoo Min, Hyung Woo Kim, Ju Sang Kim Tuberculosis and Respiratory Diseases.2023; 86(1): 67. CrossRef
Prevalence and associated factors of diabetes mellitus among patients with tuberculosis in South Korea from 2011 to 2018: a nationwide cohort study Dawoon Jeong, Jeongha Mok, Doosoo Jeon, Hee-Yeon Kang, Hee Jin Kim, Hee-Sun Kim, Jeong Mi Seo, Hongjo Choi, Young Ae Kang BMJ Open.2023; 13(3): e069642. CrossRef
Increased Healthcare Delays in Tuberculosis Patients During the First Wave of COVID-19 Pandemic in Korea: A Nationwide Cross-Sectional Study Jinsoo Min, Yousang Ko, Hyung Woo Kim, Hyeon-Kyoung Koo, Jee Youn Oh, Yun-Jeong Jeong, Hyeon Hui Kang, Kwang Joo Park, Yong Il Hwang, Jin Woo Kim, Joong Hyun Ahn, Yangjin Jegal, Ji Young Kang, Sung-Soon Lee, Jae Seuk Park, Ju Sang Kim Journal of Korean Medical Science.2022;[Epub] CrossRef
Time trend prediction and spatial–temporal analysis of multidrug-resistant tuberculosis in Guizhou Province, China, during 2014–2020 Wang Yun, Chen Huijuan, Liao Long, Lu Xiaolong, Zhang Aihua BMC Infectious Diseases.2022;[Epub] CrossRef
Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data Sun-Hong Kwon, Jin Hyun Nam, Hye-Lin Kim, Hae-Young Park, Jin-Won Kwon Frontiers in Pharmacology.2022;[Epub] CrossRef
The Impact of the COVID-19 Pandemic on Tuberculosis Case Notification and Treatment Outcomes in Eswatini Hloniphile Victory Masina, I-Feng Lin, Li-Yin Chien International Journal of Public Health.2022;[Epub] CrossRef
Trends in incidences of newly notified tuberculosis in Jeju Province, Korea, 2017-2021 Jinhee Kim, Nam-Hun Kang, Jong-Myon Bae Journal of Medicine and Life Science.2022; 19(3): 103. CrossRef
Yunhyung Kwon, So Jung Kim, Jieun Kim, Seol-yi Kim, Eun Mi Song, Eun Jung Lee, Yun Choi, Yejin Kim, Byoung ok Lim, Da Sul Kim, Duksun Choi, Hye Sung Kim, Ji Eun Park, Ji-eun Yun, Jin A. Park, Jong Rak Jung, Joo-kyoung Kim, Sang Hee Kang, Seo Yean Hong, Seung Jae Lee, Soo Jin Park, Sun Hwa Park, Sunhye Yoon, Yoonsun Kim, Yunjeong Choi, Yun Jeong Seo, Yul A Seo, Jiseon Park, Minhee Sung, Minjang Shin, Hyunjin Son, Yeonkyeng Lee, Unyeong Go, Geun-Yong Kwon
Osong Public Health Res Perspect. 2014;5(Suppl):S30-S36. Published online December 31, 2014
Objectives
This study aimed to check the status of the contact investigation in congregate settings to eradicate tuberculosis (TB) in the Republic of Korea. Methods
The “Integrated System for Disease and Public Health Management” is used for care and follow-up for patients and contacts of TB. We downloaded data for contact investigations conducted from January to December 2013. Results
A total of 1,200 contact investigations in congregate settings were carried out by 25 field investigators in 2013. We performed the status of contact investigation, TB, and LTBI rate by age, accept rate of LTBI treatment, and complete rate of LTBI treatment during 2013. A total of 1,547 index TB patients, 149,166 contacts, and 259 additional TB patients were found through the investigation. Kindergartens showed the highest LTBI rate, 19.8%, among educational facilities. The second highest was in elementary schools and the subtotal LTBI rate of educational facilities was 7.8%. Social welfare/correctional facilities and workplaces showed relatively high LTBI rates of 23.8% and 23.6%, respectively. By age, individuals >35 years showed the highest LTBI rate, followed by those aged 0–4 years, 30–34 years, and 5–9 years, with rates of 18.1%, 16.4%, and 15.4% respectively. When comparing the tuberculin skin test (TST) positive conversion ratio by facility, middle school and high school were relatively high compared to the others. The accept rate of LTBI treatment in the workplace was lowest at 63% and the complete rate in elementary schools was lowest at 76.5%. Conclusion
TB contact investigation is considered as a meaningful strategy for preventing TB outbreaks in congregate settings and decreasing the prevalence of TB in young people. Results of this study could be used to establish the LTBI management policy.
Citations
Citations to this article as recorded by
Latent Tuberculosis Cascade of Care Among Healthcare Workers: A Nationwide Cohort Analysis in Korea Between 2017 and 2018 Jinsoo Min, Hyung Woo Kim, Joon Young Choi, Ah Young Shin, Ji Young Kang, Yunhee Lee, Jun-Pyo Myong, Hyunsuk Jeong, Sanghyuk Bae, Hyeon-Kyoung Koo, Sung-Soon Lee, Jae Seuk Park, Hyeon Woo Yim, Ju Sang Kim Journal of Korean Medical Science.2022;[Epub] CrossRef
Risk of active tuberculosis development in contacts exposed to infectious tuberculosis in congregate settings in Korea Shin Young Park, Sunmi Han, Young-Man Kim, Jieun Kim, Sodam Lee, Jiyeon Yang, Un-Na Kim, Mi-sun Park Scientific Reports.2020;[Epub] CrossRef
The risk of active tuberculosis among individuals living in tuberculosis-affected households in the Republic of Korea, 2015 Jiyeon Yang, Sodam Lee, Suhyeon Oh, Sunmi Han, Shin Young Park, Youngman Kim, Jieun Kim, Mi-sun Park, Philip C. Hill PLOS ONE.2019; 14(12): e0225744. CrossRef
The Infectivity of Pulmonary Tuberculosis in Korean Army Units: Evidence from Outbreak Investigations Chang-gyo Yoon, Dong Yoon Kang, Jaehun Jung, Soo Yon Oh, Jin Beom Lee, Mi-Hyun Kim, Younsuk Seo, Hee-Jin Kim Tuberculosis and Respiratory Diseases.2019; 82(4): 298. CrossRef
Tuberculosis prevention and care in Korea: Evolution of policy and practice Unyeong Go, Misun Park, Un-Na Kim, Sodam Lee, Sunmi Han, Joosun Lee, Jiyeon Yang, Jieun Kim, Shinyoung Park, Youngman Kim, Hyosoon Yoo, Jeongok Cha, Wonseo Park, Haeyoung Kang, Hwon Kim, Guri Park, Minjung Kim, Ok Park, Hyunjin Son, Enhi Cho, Kyoungin Na, Journal of Clinical Tuberculosis and Other Mycobac.2018; 11: 28. CrossRef
The Prevalence and Risk Factors of Latent Tuberculosis Infection among Health Care Workers Working in a Tertiary Hospital in South Korea Jae Seuk Park Tuberculosis and Respiratory Diseases.2018; 81(4): 274. CrossRef